Search
P3 Health Partners Inc
PIIIAdd to Watchlist
10.750USD
-0.480-4.27%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
35.13MMarket Cap
0.04P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of P3 Health Partners Inc is 7.00, ranking 316 out of 389 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 12.50 and a low of 8.00.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
14.000
Target Price
+24.67%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
P3 Health Partners Inc
PIII
2
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is P3 Health Partners Inc's expected revenue for the next quarter?
P3 Health Partners Inc's expected revenue is 377.95M.
What is P3 Health Partners Inc's price target?
Analysts forecast that P3 Health Partners Inc's price target is USD 11.00, with the highest forecast at USD 12.50 and the lowest forecast at USD 8.00.
How have P3 Health Partners IncPIII's recent earnings per share performed?
The market expectation was USD 0.37, while P3 Health Partners IncPIII's earnings per share (EPS) for the previous quarter was USD -23.02. EPS for the next quarter is expected at USD -2.00.
What is the analyst rating for P3 Health Partners Inc?
Based on the ratings of P3 Health Partners Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
